Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells

Arthur A. Vandenbark, David Barnes, Tom Finn, Dennis N. Bourdette, Ruth Whitham, Ian Robey, Johnan Kaleeba, Bruce F. Bebo, Steven D. Miller, Halina Offner, Yuan K. Chou

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Antigen-coupled antigen-presenting cells (APC) serve as potent tolerogens for inhibiting immune responses in vivo and in vitro, apparently by providing an antigen-specific signal through the TCR in the absence of co-stimulation. Although this approach has been well studied in rodents, little is known about its effects on human T cells. We evaluated the specificity and mechanisms of tolerization of human T cells in vitro using monocyte-enriched adherent cells that were pulsed with antigen and treated with the cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI). Autologous antigen-coupled APC selectively tolerized T cells of the T(h)1 but not T(h)2 lineage through a mechanism that involved both antigen-specific and antigen-non-specific elements. The tolerization process was dependent on the ECDI and antigen concentration, and the coupling time, and was reflected by initial up-regulation of CD25. However, upon re-stimulation with fresh APC and antigen, tolerized T(h)1 cells failed to proliferate or to produce T(h)1 cytokine message or secreted protein, had decreased expression of CD25, CD28 and B7 and increased expression of MHC class II molecules, and demonstrated an enhanced commitment to apoptosis. T(h)1 cell tolerization could be prevented by adding anti-CD28 antibody, IL-2 or untreated APC at the same time as the ECDI/antigen-coupled APC, or reversed by adding anti-CD28 antibody or IL-2 upon re-stimulation with fresh APC plus antigen. Thus, the tolerizing effect of ECDI/antigen-coupled APC on human T(h)1 cells appears to involve a reversible anergy mechanism leading to apoptosis, whereby the targeted T cells receive full or partial activation through the TCR, without coordinate co-stimulation. These data suggest dichotomous signaling requirements for inactivating cells of the T(h)1 and T(h)2 lineages that may have important implications for treatment of T(h)1-mediated autoimmune or inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalInternational Immunology
Volume12
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Ethyldimethylaminopropyl Carbodiimide
Antigen-Presenting Cells
Apoptosis
Antigens
T-Lymphocytes
Interleukin-2
Anti-Idiotypic Antibodies
Viral Tumor Antigens
Autoantigens
Monocytes
Rodentia
Up-Regulation
Cytokines

Keywords

  • Altered antigen-presenting cells
  • Human T cells
  • Tolerance induction

ASJC Scopus subject areas

  • Immunology

Cite this

Vandenbark, A. A., Barnes, D., Finn, T., Bourdette, D. N., Whitham, R., Robey, I., ... Chou, Y. K. (2000). Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells. International Immunology, 12(1), 57-66.

Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells. / Vandenbark, Arthur A.; Barnes, David; Finn, Tom; Bourdette, Dennis N.; Whitham, Ruth; Robey, Ian; Kaleeba, Johnan; Bebo, Bruce F.; Miller, Steven D.; Offner, Halina; Chou, Yuan K.

In: International Immunology, Vol. 12, No. 1, 2000, p. 57-66.

Research output: Contribution to journalArticle

Vandenbark, AA, Barnes, D, Finn, T, Bourdette, DN, Whitham, R, Robey, I, Kaleeba, J, Bebo, BF, Miller, SD, Offner, H & Chou, YK 2000, 'Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells', International Immunology, vol. 12, no. 1, pp. 57-66.
Vandenbark, Arthur A. ; Barnes, David ; Finn, Tom ; Bourdette, Dennis N. ; Whitham, Ruth ; Robey, Ian ; Kaleeba, Johnan ; Bebo, Bruce F. ; Miller, Steven D. ; Offner, Halina ; Chou, Yuan K. / Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells. In: International Immunology. 2000 ; Vol. 12, No. 1. pp. 57-66.
@article{52fac9fadcc74ab9b56d8d1eb8031358,
title = "Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells",
abstract = "Antigen-coupled antigen-presenting cells (APC) serve as potent tolerogens for inhibiting immune responses in vivo and in vitro, apparently by providing an antigen-specific signal through the TCR in the absence of co-stimulation. Although this approach has been well studied in rodents, little is known about its effects on human T cells. We evaluated the specificity and mechanisms of tolerization of human T cells in vitro using monocyte-enriched adherent cells that were pulsed with antigen and treated with the cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI). Autologous antigen-coupled APC selectively tolerized T cells of the T(h)1 but not T(h)2 lineage through a mechanism that involved both antigen-specific and antigen-non-specific elements. The tolerization process was dependent on the ECDI and antigen concentration, and the coupling time, and was reflected by initial up-regulation of CD25. However, upon re-stimulation with fresh APC and antigen, tolerized T(h)1 cells failed to proliferate or to produce T(h)1 cytokine message or secreted protein, had decreased expression of CD25, CD28 and B7 and increased expression of MHC class II molecules, and demonstrated an enhanced commitment to apoptosis. T(h)1 cell tolerization could be prevented by adding anti-CD28 antibody, IL-2 or untreated APC at the same time as the ECDI/antigen-coupled APC, or reversed by adding anti-CD28 antibody or IL-2 upon re-stimulation with fresh APC plus antigen. Thus, the tolerizing effect of ECDI/antigen-coupled APC on human T(h)1 cells appears to involve a reversible anergy mechanism leading to apoptosis, whereby the targeted T cells receive full or partial activation through the TCR, without coordinate co-stimulation. These data suggest dichotomous signaling requirements for inactivating cells of the T(h)1 and T(h)2 lineages that may have important implications for treatment of T(h)1-mediated autoimmune or inflammatory diseases.",
keywords = "Altered antigen-presenting cells, Human T cells, Tolerance induction",
author = "Vandenbark, {Arthur A.} and David Barnes and Tom Finn and Bourdette, {Dennis N.} and Ruth Whitham and Ian Robey and Johnan Kaleeba and Bebo, {Bruce F.} and Miller, {Steven D.} and Halina Offner and Chou, {Yuan K.}",
year = "2000",
language = "English (US)",
volume = "12",
pages = "57--66",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Differential susceptibility of human T(h)1 versus T(h)2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells

AU - Vandenbark, Arthur A.

AU - Barnes, David

AU - Finn, Tom

AU - Bourdette, Dennis N.

AU - Whitham, Ruth

AU - Robey, Ian

AU - Kaleeba, Johnan

AU - Bebo, Bruce F.

AU - Miller, Steven D.

AU - Offner, Halina

AU - Chou, Yuan K.

PY - 2000

Y1 - 2000

N2 - Antigen-coupled antigen-presenting cells (APC) serve as potent tolerogens for inhibiting immune responses in vivo and in vitro, apparently by providing an antigen-specific signal through the TCR in the absence of co-stimulation. Although this approach has been well studied in rodents, little is known about its effects on human T cells. We evaluated the specificity and mechanisms of tolerization of human T cells in vitro using monocyte-enriched adherent cells that were pulsed with antigen and treated with the cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI). Autologous antigen-coupled APC selectively tolerized T cells of the T(h)1 but not T(h)2 lineage through a mechanism that involved both antigen-specific and antigen-non-specific elements. The tolerization process was dependent on the ECDI and antigen concentration, and the coupling time, and was reflected by initial up-regulation of CD25. However, upon re-stimulation with fresh APC and antigen, tolerized T(h)1 cells failed to proliferate or to produce T(h)1 cytokine message or secreted protein, had decreased expression of CD25, CD28 and B7 and increased expression of MHC class II molecules, and demonstrated an enhanced commitment to apoptosis. T(h)1 cell tolerization could be prevented by adding anti-CD28 antibody, IL-2 or untreated APC at the same time as the ECDI/antigen-coupled APC, or reversed by adding anti-CD28 antibody or IL-2 upon re-stimulation with fresh APC plus antigen. Thus, the tolerizing effect of ECDI/antigen-coupled APC on human T(h)1 cells appears to involve a reversible anergy mechanism leading to apoptosis, whereby the targeted T cells receive full or partial activation through the TCR, without coordinate co-stimulation. These data suggest dichotomous signaling requirements for inactivating cells of the T(h)1 and T(h)2 lineages that may have important implications for treatment of T(h)1-mediated autoimmune or inflammatory diseases.

AB - Antigen-coupled antigen-presenting cells (APC) serve as potent tolerogens for inhibiting immune responses in vivo and in vitro, apparently by providing an antigen-specific signal through the TCR in the absence of co-stimulation. Although this approach has been well studied in rodents, little is known about its effects on human T cells. We evaluated the specificity and mechanisms of tolerization of human T cells in vitro using monocyte-enriched adherent cells that were pulsed with antigen and treated with the cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI). Autologous antigen-coupled APC selectively tolerized T cells of the T(h)1 but not T(h)2 lineage through a mechanism that involved both antigen-specific and antigen-non-specific elements. The tolerization process was dependent on the ECDI and antigen concentration, and the coupling time, and was reflected by initial up-regulation of CD25. However, upon re-stimulation with fresh APC and antigen, tolerized T(h)1 cells failed to proliferate or to produce T(h)1 cytokine message or secreted protein, had decreased expression of CD25, CD28 and B7 and increased expression of MHC class II molecules, and demonstrated an enhanced commitment to apoptosis. T(h)1 cell tolerization could be prevented by adding anti-CD28 antibody, IL-2 or untreated APC at the same time as the ECDI/antigen-coupled APC, or reversed by adding anti-CD28 antibody or IL-2 upon re-stimulation with fresh APC plus antigen. Thus, the tolerizing effect of ECDI/antigen-coupled APC on human T(h)1 cells appears to involve a reversible anergy mechanism leading to apoptosis, whereby the targeted T cells receive full or partial activation through the TCR, without coordinate co-stimulation. These data suggest dichotomous signaling requirements for inactivating cells of the T(h)1 and T(h)2 lineages that may have important implications for treatment of T(h)1-mediated autoimmune or inflammatory diseases.

KW - Altered antigen-presenting cells

KW - Human T cells

KW - Tolerance induction

UR - http://www.scopus.com/inward/record.url?scp=0033967865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033967865&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 57

EP - 66

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 1

ER -